{"id":"https://openalex.org/W2142913791","doi":"https://doi.org/10.1158/1541-7786.mcr-13-0581","title":"Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant\u2013Expressing Melanoma","display_name":"Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant\u2013Expressing Melanoma","publication_year":2014,"publication_date":"2014-02-11","ids":{"openalex":"https://openalex.org/W2142913791","doi":"https://doi.org/10.1158/1541-7786.mcr-13-0581","mag":"2142913791","pmid":"https://pubmed.ncbi.nlm.nih.gov/24520098","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4020954"},"language":"en","primary_location":{"id":"doi:10.1158/1541-7786.mcr-13-0581","doi":"https://doi.org/10.1158/1541-7786.mcr-13-0581","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1541-7786.mcr-13-0581","pdf_url":null,"source":{"id":"https://openalex.org/S192067876","display_name":"Molecular Cancer Research","issn_l":"1541-7786","issn":["1541-7786","1557-3125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4020954","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050694888","display_name":"Edward J. Hartsough","orcid":"https://orcid.org/0000-0002-5109-3978","observed_orcids":["https://orcid.org/0000-0002-5109-3978"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward J. Hartsough","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I149251103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033787308","display_name":"Kevin J. Basile","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin J. Basile","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I149251103"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062746446","display_name":"Andrew E. Aplin","orcid":"https://orcid.org/0000-0002-2734-3244","observed_orcids":["https://orcid.org/0000-0002-2734-3244"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew E. Aplin","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Cancer Biology and 2Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I149251103"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5062746446"],"corresponding_institution_ids":["https://openalex.org/I149251103"],"apc_list":null,"apc_paid":null,"fwci":2.3909,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.89897895,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"12","issue":"5","first_page":"795","last_page":"802"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/raf-inhibitor-resistance","display_name":"RAF inhibitor resistance","score":0.8240000009536743},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8579999804496765},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/plx4720","display_name":"PLX4720","score":0.9559999704360962},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9210000038146973},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.8659999966621399},{"id":"https://openalex.org/keywords/mek-inhibition","display_name":"MEK inhibition","score":0.8270000219345093},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.9459999799728394},{"id":"https://openalex.org/keywords/tumor-fitness","display_name":"tumor fitness","score":0.5130000114440918}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9262045621871948},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.8612651824951172},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7890219688415527},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.7707510590553284},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7290784120559692},{"id":"https://openalex.org/C2780989783","wikidata":"https://www.wikidata.org/wiki/Q7578557","display_name":"splice","level":3,"score":0.6934046149253845},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.662734866142273},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.578354001045227},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5565024614334106},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.55058753490448},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.4682304263114929},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4335886538028717},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.41532281041145325},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1649320423603058},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.10408711433410645},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020033","descriptor_name":"Protein Isoforms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1158/1541-7786.mcr-13-0581","doi":"https://doi.org/10.1158/1541-7786.mcr-13-0581","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1541-7786.mcr-13-0581","pdf_url":null,"source":{"id":"https://openalex.org/S192067876","display_name":"Molecular Cancer Research","issn_l":"1541-7786","issn":["1541-7786","1557-3125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Research","raw_type":"journal-article"},{"id":"pmid:24520098","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24520098","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer research : MCR","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4020954","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4020954","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Res","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.913.6832","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.913.6832","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mcr.aacrjournals.org/content/12/5/795.full.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.914.9991","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.914.9991","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mcr.aacrjournals.org/content/early/2014/04/22/1541-7786.MCR-13-0581.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4020954","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4020954","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Res","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5428753359","display_name":"FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma","funder_award_id":"R01CA160495","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000897668","display_name":"Translational Research in Cancer","funder_award_id":"P30CA056036","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1892632640","https://openalex.org/W1966453709","https://openalex.org/W1982443780","https://openalex.org/W2011261819","https://openalex.org/W2017187984","https://openalex.org/W2032211985","https://openalex.org/W2038212896","https://openalex.org/W2038388329","https://openalex.org/W2043058822","https://openalex.org/W2053473615","https://openalex.org/W2058390096","https://openalex.org/W2061261084","https://openalex.org/W2065411693","https://openalex.org/W2068882576","https://openalex.org/W2072984024","https://openalex.org/W2083435672","https://openalex.org/W2100158834","https://openalex.org/W2100614336","https://openalex.org/W2106543129","https://openalex.org/W2128542677","https://openalex.org/W2129223456","https://openalex.org/W2132197524","https://openalex.org/W2136222819","https://openalex.org/W2139707889","https://openalex.org/W2141674733","https://openalex.org/W2156078931","https://openalex.org/W2163188200","https://openalex.org/W2168143310","https://openalex.org/W2168608120"],"related_works":["https://openalex.org/W7099087579","https://openalex.org/W2002028874","https://openalex.org/W2043058822","https://openalex.org/W4253801673","https://openalex.org/W2956010168","https://openalex.org/W2038655858","https://openalex.org/W2033014187","https://openalex.org/W1995437676","https://openalex.org/W1515381216","https://openalex.org/W2081295565"],"abstract_inverted_index":{"UNLABELLED:":[0],"Resistance":[1],"to":[2,49,71,133],"RAF":[3,28,50,61,87,175,183],"inhibitors":[4,29,51],"such":[5],"as":[6,70],"vemurafenib":[7,110],"and":[8,34,102],"dabrafenib":[9],"is":[10,52],"a":[11,80,139],"major":[12],"clinical":[13],"problem":[14],"in":[15,66,83,100,103,105,115,141],"the":[16,84,106,109,116,147,153],"treatment":[17,32,145],"of":[18,47,56,86,108,118,127,174],"melanoma.":[19],"Patients":[20],"with":[21,114,146],"mutant":[22,57,75,93,163],"BRAF":[23,58,76,94,121,164],"melanoma":[24,167,185],"that":[25,162,182],"progress":[26],"on":[27],"have":[30],"limited":[31],"options,":[33],"drug":[35],"removal":[36],"from":[37,188],"resistant":[38],"tumors":[39],"may":[40],"elicit":[41],"multiple":[42],"effects.":[43],"A":[44],"frequent":[45],"mechanism":[46],"resistance":[48],"caused":[53],"by":[54,157,171],"expression":[55],"splice":[59,77,95,122,165],"variants.":[60],"inhibitor-resistant":[62,184],"cell":[63],"lines,":[64],"generated":[65],"vivo,":[67],"were":[68],"tested":[69],"whether":[72],"or":[73],"not":[74],"variants":[78,96],"confer":[79],"fitness":[81,154],"advantage":[82],"presence":[85,107],"inhibitor.":[88,119],"Critically,":[89],"cells":[90,124,168,186],"expressing":[91],"distinct":[92],"grow":[97],"more":[98],"efficiently":[99],"vitro":[101],"vivo":[104],"analog,":[111],"PLX4720,":[112],"compared":[113],"absence":[117],"PLX4720-treated":[120],"variant-expressing":[123,166],"exhibited":[125],"levels":[126,143],"phospho-extracellular":[128],"signal-regulated":[129],"kinase":[130],"(ERK)1/2":[131],"comparable":[132],"untreated":[134],"parental":[135],"cells.":[136],"In":[137],"addition,":[138],"reduction":[140],"phospho-ERK1/2":[142],"following":[144],"MEK":[148],"inhibitor,":[149],"trametinib":[150],"(GSK1120212)":[151],"phenocopied":[152],"benefit":[155,187],"provided":[156],"PLX4720.":[158],"These":[159],"data":[160],"indicate":[161],"are":[169],"benefited":[170],"defined":[172],"concentrations":[173],"inhibitors.":[176],"IMPLICATIONS:":[177],"This":[178],"study":[179],"provides":[180],"evidence":[181],"continued":[189],"therapy.":[190]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":8}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}